Skip to main content
Addgene

LB595 (Bcl-2 promoter CRE mut)
(Plasmid #15243)

Full plasmid sequence is not available for this item.

Loading...

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 15243 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pBSII KS+
  • Backbone size w/o insert (bp) 2961
  • Vector type
    Bacterial Expression, Luciferase

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    DH5alpha
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    B-cell lymphoma/leukemia-2
  • Alt name
    Bcl-2
  • Species
    H. sapiens (human)
  • Insert Size (bp)
    354
  • Mutation
    Mutated CRE site at -1537 changed from GTGACGTTA to GGGCCTTTA
  • Entrez Gene
    BCL2 (a.k.a. Bcl-2, PPP1R50)
  • Tag / Fusion Protein
    • Luciferase (C terminal on backbone)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site SacII (not destroyed)
  • 3′ cloning site XhoI (not destroyed)
  • 5′ sequencing primer T7
  • 3′ sequencing primer T3
  • (Common Sequencing Primers)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Michael Cleary, Stanford University

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    LB595 (Bcl-2 promoter CRE mut) was a gift from Linda Boxer (Addgene plasmid # 15243 ; http://n2t.net/addgene:15243 ; RRID:Addgene_15243)
  • For your References section:

    NF-kappaB activates Bcl-2 expression in t(14;18) lymphoma cells. Heckman CA, Mehew JW, Boxer LM. Oncogene. 2002 May 30. 21(24):3898-908. 10.1038/sj.onc.1205483 PubMed 12032828